|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TAGLN2 |
Gene summary for TAGLN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TAGLN2 | Gene ID | 8407 |
| Gene name | transgelin 2 | |
| Gene Alias | HA1756 | |
| Cytomap | 1q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | P37802 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8407 | TAGLN2 | GSM4909282 | Human | Breast | IDC | 2.16e-98 | 8.81e-01 | -0.0288 |
| 8407 | TAGLN2 | GSM4909285 | Human | Breast | IDC | 3.33e-32 | 5.69e-01 | 0.21 |
| 8407 | TAGLN2 | GSM4909286 | Human | Breast | IDC | 6.38e-10 | -3.97e-01 | 0.1081 |
| 8407 | TAGLN2 | GSM4909287 | Human | Breast | IDC | 7.09e-18 | 4.06e-01 | 0.2057 |
| 8407 | TAGLN2 | GSM4909288 | Human | Breast | IDC | 7.59e-05 | 8.66e-02 | 0.0988 |
| 8407 | TAGLN2 | GSM4909289 | Human | Breast | IDC | 3.18e-05 | 4.93e-01 | 0.1064 |
| 8407 | TAGLN2 | GSM4909291 | Human | Breast | IDC | 2.84e-28 | 6.15e-01 | 0.1753 |
| 8407 | TAGLN2 | GSM4909293 | Human | Breast | IDC | 4.58e-02 | 2.42e-01 | 0.1581 |
| 8407 | TAGLN2 | GSM4909294 | Human | Breast | IDC | 3.32e-03 | -5.28e-02 | 0.2022 |
| 8407 | TAGLN2 | GSM4909295 | Human | Breast | IDC | 3.51e-08 | 4.31e-01 | 0.0898 |
| 8407 | TAGLN2 | GSM4909296 | Human | Breast | IDC | 1.46e-16 | 1.80e-01 | 0.1524 |
| 8407 | TAGLN2 | GSM4909297 | Human | Breast | IDC | 1.57e-23 | -3.37e-01 | 0.1517 |
| 8407 | TAGLN2 | GSM4909298 | Human | Breast | IDC | 2.42e-04 | 2.45e-01 | 0.1551 |
| 8407 | TAGLN2 | GSM4909301 | Human | Breast | IDC | 1.54e-20 | -6.14e-01 | 0.1577 |
| 8407 | TAGLN2 | GSM4909309 | Human | Breast | IDC | 3.83e-07 | 1.07e-01 | 0.0483 |
| 8407 | TAGLN2 | GSM4909311 | Human | Breast | IDC | 8.31e-43 | -4.38e-01 | 0.1534 |
| 8407 | TAGLN2 | GSM4909312 | Human | Breast | IDC | 1.87e-10 | -3.41e-02 | 0.1552 |
| 8407 | TAGLN2 | GSM4909313 | Human | Breast | IDC | 9.87e-11 | 1.53e-01 | 0.0391 |
| 8407 | TAGLN2 | GSM4909315 | Human | Breast | IDC | 5.65e-54 | 6.22e-01 | 0.21 |
| 8407 | TAGLN2 | GSM4909316 | Human | Breast | IDC | 1.92e-29 | 5.92e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| TAGLN2 | CD8TEXP | Breast | DCIS | S100A10,VIM,LMNA, etc. | 5.59e-02 |  |
| TAGLN2 | CD8TEXP | Breast | Healthy | S100A10,VIM,LMNA, etc. | 2.31e-02 |  |
| TAGLN2 | CD8TEX | Breast | Healthy | S100A10,VIM,LMNA, etc. | 1.21e-02 | |
| TAGLN2 | CD8TEX | Breast | IDC | S100A10,VIM,LMNA, etc. | 5.51e-02 |  |
| TAGLN2 | CD8TEXP | Breast | IDC | S100A10,VIM,LMNA, etc. | 4.83e-02 | |
| TAGLN2 | M1MAC | Breast | Precancer | S100A10,VIM,LMNA, etc. | 4.39e-02 |  |
| TAGLN2 | CD8TEXINT | Breast | Precancer | S100A10,VIM,LMNA, etc. | 3.83e-02 | |
| TAGLN2 | GOB | Colorectum | SER | OXR1,OAZ1,CFL1, etc. | 4.06e-01 |  |
| TAGLN2 | PVA | Endometrium | Healthy | HLA-B,B2M,TMSB10, etc. | 3.44e-01 |  |
| TAGLN2 | M1MAC | Oral cavity | EOLP | CRIP1,LMNA,EMP3, etc. | 1.06e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TAGLN2 | SNV | Missense_Mutation | c.460N>C | p.Gly154Arg | p.G154R | P37802 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TAGLN2 | insertion | Frame_Shift_Ins | novel | c.428_429insATGGCTCTCGAGGGCAGAGCTGGCACCAGCCCTTGAGCCAACAGCAA | p.Met143IlefsTer24 | p.M143Ifs*24 | P37802 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| TAGLN2 | SNV | Missense_Mutation | rs369414441 | c.607C>T | p.Arg203Cys | p.R203C | P37802 | protein_coding | tolerated(0.14) | benign(0.033) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TAGLN2 | SNV | Missense_Mutation | novel | c.262N>C | p.Asn88His | p.N88H | P37802 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| TAGLN2 | SNV | Missense_Mutation | c.300G>T | p.Lys100Asn | p.K100N | P37802 | protein_coding | tolerated(0.11) | benign(0.205) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TAGLN2 | SNV | Missense_Mutation | novel | c.472G>A | p.Val158Ile | p.V158I | P37802 | protein_coding | deleterious(0.04) | benign(0.015) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| TAGLN2 | SNV | Missense_Mutation | novel | c.239N>A | p.Gly80Asp | p.G80D | P37802 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TAGLN2 | SNV | Missense_Mutation | novel | c.522N>T | p.Lys174Asn | p.K174N | P37802 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TAGLN2 | SNV | Missense_Mutation | novel | c.336N>T | p.Glu112Asp | p.E112D | P37802 | protein_coding | deleterious(0.01) | benign(0.344) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| TAGLN2 | SNV | Missense_Mutation | rs373828343 | c.41C>T | p.Pro14Leu | p.P14L | P37802 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.988) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |